{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T14:10:05Z","timestamp":1789049405174,"version":"build-2803163510"},"reference-count":36,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2022,9,27]],"date-time":"2022-09-27T00:00:00Z","timestamp":1664236800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["dom-pubs.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Diabetes Obesity Metabolism"],"published-print":{"date-parts":[[2023,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aim<\/jats:title>\n                    <jats:p>To investigate the impact of sodium\u2010glucose cotransporter 2 (SGLT2) inhibitors on the risk of incident heart failure and adverse cardiovascular outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>All patients with diabetes who were registered between January 2018 and December 2019 were identified from a federated electronic medical record database (TriNetX) and followed up for 2\u2009years. A 1:1 propensity\u2010score matching (PSM) analysis was performed to balance the SGLT2 inhibitor and non\u2010SGLT2 inhibitor cohorts. The primary outcome was incident heart failure. Secondary outcomes included all\u2010cause mortality, cardiac arrest, ventricular tachycardia\/ventricular fibrillation (VT\/VF), incident atrial fibrillation (AF), ischaemic stroke\/transient ischaemic attack (TIA), composite of arterial and venous thrombotic events, and composite of incident VT\/VF and cardiac arrest.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 131 189\u00a0and 2\u2009692 985 patients were treated with and without SGLT2 inhibitors, respectively. After PSM, 131 188 patients remained in each group. The risk of incident heart failure was significantly lower in the SGLT2 inhibitor cohort compared to the non\u2010SGLT2 inhibitor cohort (hazard ratio [HR] 0.70, 95% confidence interval [CI] 0.68\u20100.73). SGLT2 inhibitor use was also associated with a significantly lower risk of all\u2010cause mortality (HR 0.61, 95% CI 0.58\u20100.64), cardiac arrest (HR 0.70, 95% CI 0.63\u20100.78), incident AF (HR 0.81, 95% CI 0.76\u20100.84), ischaemic stroke\/TIA (HR 0.90, 95% CI 0.88\u20100.93), composite of arterial and venous thrombotic events (HR 0.90, 95% CI 0.88\u20100.92), and composite of incident VT\/VF and cardiac arrest (HR 0.76, 95% CI 0.71\u20100.81). There were no significant differences for VT\/VF (HR 0.94, 95% CI 0.88\u20101.00).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Use of SGLT2 inhibitors was associated with a significant reduction in the risk of incident heart failure and adverse cardiovascular outcomes but not ventricular arrhythmias.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/dom.14854","type":"journal-article","created":{"date-parts":[[2022,8,31]],"date-time":"2022-08-31T03:36:13Z","timestamp":1661916973000},"page":"602-610","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":44,"title":["Incident heart failure, arrhythmias and cardiovascular outcomes with sodium\u2010glucose cotransporter 2 (\n                    <scp>SGLT2<\/scp>\n                    ) inhibitor use in patients with diabetes: Insights from a global federated electronic medical record database"],"prefix":"10.1111","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9477-7245","authenticated-orcid":false,"given":"Ameenathul Mazaya","family":"Fawzy","sequence":"first","affiliation":[{"name":"Liverpool Centre for Cardiovascular Science University of Liverpool and Liverpool Heart &amp; Chest Hospital  Liverpool UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0492-6241","authenticated-orcid":false,"given":"Jos\u00e9 Miguel","family":"Rivera\u2010Caravaca","sequence":"additional","affiliation":[{"name":"Liverpool Centre for Cardiovascular Science University of Liverpool and Liverpool Heart &amp; Chest Hospital  Liverpool UK"},{"name":"Department of Cardiology, Hospital Cl\u00ednico Universitario Virgen de la Arrixaca University of Murcia, Instituto Murciano de Investigaci\u00f3n Biosanitaria (IMIB\u2010Arrixaca), CIBERCV  Murcia Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paula","family":"Underhill","sequence":"additional","affiliation":[{"name":"TriNetX LLC  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Fauchier","sequence":"additional","affiliation":[{"name":"Service de Cardiologie Centre Hospitalier Universitaire Trousseau  Tours France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory Y. H.","family":"Lip","sequence":"additional","affiliation":[{"name":"Liverpool Centre for Cardiovascular Science University of Liverpool and Liverpool Heart &amp; Chest Hospital  Liverpool UK"},{"name":"Department of Clinical Medicine Aalborg University  Aalborg Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2022,9,27]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMOA1911303"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1093\/EURHEARTJ\/EHAB368"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMOA1812389\/SUPPL_FILE\/NEJMOA1812389_DATA\u2010SHARING.PDF"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMOA1504720\/SUPPL_FILE\/NEJMOA1504720_DISCLOSURES.PDF"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMOA1611925\/SUPPL_FILE\/NEJMOA1611925_DISCLOSURES.PDF"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMOA2022190\/SUPPL_FILE\/NEJMOA2022190_DATA\u2010SHARING.PDF"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMOA2030183\/SUPPL_FILE\/NEJMOA2030183_DATA\u2010SHARING.PDF"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1200\/CCI.17.00067"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.13063\/2327\u20109214.1244"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/J.CLINTHERA.2016.08.008"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1038\/S41569\u2010020\u20100406\u20108"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/DOM.12127"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1186\/S12933\u2010021\u201001295\u20106\/TABLES\/3"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.2337\/DC17\u20101096"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/J.JACC.2018.01.085"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1002\/EHF2.13830"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/DOM.14189"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/DOM.14593"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598\u2010021\u201094945\u20104"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/J.JACC.2018.03.009"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.119.044183"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.119.017483"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1097\/FJC.0000000000001183"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.109.914911"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.3390\/MOLECULES25163606"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/J.HRTHM.2021.03.028"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.1093\/EUROPACE\/EUAB177"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.1186\/S12933\u2010021\u201001293\u20108\/TABLES\/2"},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.1002\/DMRR.3174"},{"key":"e_1_2_8_31_1","doi-asserted-by":"publisher","DOI":"10.1136\/BMJ.K4365"},{"key":"e_1_2_8_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/J.AMJMED.2020.10.046"},{"key":"e_1_2_8_33_1","doi-asserted-by":"publisher","DOI":"10.1186\/S12933\u2010021\u201001276\u20109\/TABLES\/4"},{"key":"e_1_2_8_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213\u20108587(19)30384\u20105"},{"key":"e_1_2_8_35_1","unstructured":"Dapagliflozin effects on cardiovascular events in patients with an acute heart attack \u2010 full text view.ClinicalTrials.gov. Accessed February 21 2022.https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04564742"},{"key":"e_1_2_8_36_1","unstructured":"Dapagliflozin to prevent atrial fibrillation recurrence after Transcatheter pulmonary venous isolation. \u2010 full text view.ClinicalTrials.gov. Accessed February 21 2022.https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04780438?cond=sodium-glucose+co-transporter2&draw=8&rank=44"},{"key":"e_1_2_8_37_1","unstructured":"SGLT2 inhibitors in ATTR \u2010 full text view.ClinicalTrials.gov. Accessed February 21 2022.https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05233163?cond=sodium-glucose+co-transporter2&draw=5&rank=18"}],"container-title":["Diabetes, Obesity and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/dom.14854","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/dom.14854","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/dom-pubs.pericles-prod.literatumonline.com\/doi\/pdf\/10.1111\/dom.14854","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T23:19:05Z","timestamp":1761866345000},"score":1,"resource":{"primary":{"URL":"https:\/\/dom-pubs.pericles-prod.literatumonline.com\/doi\/10.1111\/dom.14854"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,27]]},"references-count":36,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,2]]}},"alternative-id":["10.1111\/dom.14854"],"URL":"https:\/\/doi.org\/10.1111\/dom.14854","archive":["Portico"],"relation":{"has-review":[{"id-type":"doi","id":"10.1111\/DOM.14854\/v1\/decision1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.14854\/v1\/review1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.14854\/v1\/review2","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.14854\/v2\/review1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.14854\/v2\/response1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.14854\/v2\/decision1","asserted-by":"object"}]},"ISSN":["1462-8902","1463-1326"],"issn-type":[{"value":"1462-8902","type":"print"},{"value":"1463-1326","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,27]]},"assertion":[{"value":"2022-06-29","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-08-28","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-09-27","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}